PARP inhibitor therapy is an effective treatment option for patients with HER2-negative locally advanced or metastatic breast cancer and germline BRCA1/2 mutation.1,2 Identifying your patients with germline BRCA1/2 mutations is the first step to offering this new targeted therapy in your practice.


Include Germline BRCA1/2 Testing in Your Metastatic
Breast Cancer Workup

According to the NCCN Guidelines®, for patients with recurrent or Stage IV HER2-negative breast cancer eligible for single-agent therapy, strongly consider germline BRCA1/2 testing during patient workup.3

No family history is needed for patients with metastatic breast cancer to meet genetic testing guidelines.

Confidently Determine BRCA1/2 Status for
PARP Inhibitor Therapy

BRACAnalysis CDx® was designed and FDA-approved to quickly provide accurate germline BRCA1/2 reports so you can confidently recommend an appropriate PARP inhibitor for your patient without delay. Once Myriad receives the sample, you will receive the results of the BRACAnalysis CDx test in less than two weeks.

Explore Patient Information and Indications for FDA-Approved PARP Inhibitors


  1. Robson et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med (2018). 377:523-533.
  2. Litton et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA mutation. N Engl J Med 2018;379:753-63.
  3. Referenced with permission from the NCCN: NCCN® Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 3.2019 BRCA-1. ©National Comprehensive Cancer Network, Inc. 2018.